News | April 07, 2010

Defibrillator Maker Pleads Guilty to Not Reporting Safety Problems

April 7, 2010 – A medical manufacturer pleaded guilty Monday to criminal violations for improper reporting of short-circuit failures of three models of its implantable cardioverter defibrillators (ICDs), the Justice Department announced. The company also agreed to pay more than $296 million in damages.

Guidant LLC admitted criminal wrongdoing after a four-year investigation into its handling of the short-circuiting failures. The ICD models include the Ventak? Prizm 2 DR (Model 1861) and the Contak Renewal (Models H135 and H155). Guidant’s ?Cardiac Rhythm Management division, which produced the defibrillators, is headquartered in ?Arden Hills, Minnesota. Guidant is now owned by Boston Scientific.

“The entry of a guilty plea by Guidant and the proposed resolution would?represent the largest criminal penalty ever imposed on a device manufacturer for violating the Food Drug and Cosmetic Act,” said Commissioner of Food and Drugs Margaret A. Hamburg,?M.D. “The FDA will continue to commit enforcement resources to seeking this type of criminal resolution and stiff sanctions when device manufacturers fail to adhere to the statutory and?regulatory requirements that exist to ensure the safety and efficacy of their products.”

The plea was made in St. Paul, Minn., before U.S.?District Court Judge Donovan W. Frank. Under the terms of the plea agreement with the Justice Department to resolve the charges,?which must still be approved by Judge Frank, Guidant pleaded guilty to with holding?information from the U.S. Food and Drug Administration (FDA) regarding catastrophic failures?in some of its devices. Specifically, Guidant admitted to: 1) making a materially false?statement in a required submission to the FDA with regard to the Ventak Prizm 2DR device; and?(2) failing to notify the FDA of a "correction" to the Contak Renewal devices, which the?company made to reduce a risk to health caused by the devices. As a result of these offenses, the agreement calls for Guidant to pay a combined criminal penalty in excess of $296 million.

“Guidant’s guilty plea today is about accountability,” said Assistant Attorney General?Tony West, who heads the Justice Department’s Civil Division. “This successful prosecution?serves as an important wake up call to all those who seek to withhold vital information about?public health and safety. We will continue our efforts to prosecute those who jeopardize public?health by evading their reporting obligations to the FDA.”

“The guilty plea today should serve as a reminder and deterrent to those who would?break the laws requiring honesty and cooperation with government regulators whose mission is?to protect the health and safety of the public,” said Frank J. Magill, Acting U.S. Attorney in this?case for the District of Minnesota. “The health care laws are as important as ever. When?medical device and pharmaceutical companies fail to live up to their legal obligations, serious?criminal consequences will follow.”

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init